NCT05573126 - Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 11, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions

Hormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast Cancer

Interventions

DRUG

Vosilasarm

Vosilasarm is an orally administered investigational selective androgen receptor modulator (SARM)

DRUG

Elacestrant

Oral SERD

DRUG

Everolimus

mTOR Inhibitor

Trial Locations (14)

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

28034

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

28041

RECRUITING

Hospital 12 de Octubre, Usera

28223

RECRUITING

NEXT Oncology Hospital Quironsalud, Madrid

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

48202

RECRUITING

Henry Ford Hospital, Detroit

75246

RECRUITING

Texas Oncology Baylor University Medical Center, Dallas

06520

RECRUITING

Yale School of Medicine, New Haven

02114

RECRUITING

Massachusetts General Hospital, Boston

08035

RECRUITING

Hospital Universitari Vall d'Hebron (VHIO), Barcelona

W1G 6AD

RECRUITING

Sarah Cannon Research Institute UK, London

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

CH63 4JY

RECRUITING

The Clatterbridge Cancer Centre, Liverpool